News
Hemostatic powder noninferior in nonvariceal upper GI bleeds
December 6, 2021
TC-325 hemostatic powder compares well with standard endoscopic treatment of acute nonvariceal gastrointestinal bleeding in a new study.
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
News
COVID-19 update: Transmission 5% or less among close contacts
March 11, 2020
New insights from China, CDC
News
Some infected patients could show COVID-19 symptoms after quarantine
March 9, 2020
Longer quarantine could be considered in highest-risk scenarios, but benefits must be weighed against costs to public health and the quarantined patients.
![1]()
News
CMS issues guidance on containing spread of coronavirus
March 5, 2020
The agency published two guidance documents related to helping contain the spread of the coronavirus, primarily aimed at ensuring that health care providers are implementing proper infection control procedures.
![1]()
News
Updated international consensus recommendations on management of acute upper GI bleeding
October 21, 2019
Updated guidelines on management of nonvariceal acute upper GI bleeding address questions on endoscopic techniques and pharmacologic management.
![1]()
News
Rivaroxaban tied to higher GI bleeding than other NOACs
June 17, 2019
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
News
No difference between PPI prophylaxis, placebo for GI bleeding
December 6, 2018
There was no significant difference in mortality between critically ill patients who received pantoprazole prophylaxis for gastrointestinal bleeding, and those who received placebo.
![1]()
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
May 4, 2018
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
![1]()
News
Idarucizumab reversed dabigatran completely and rapidly in study
July 11, 2017
One drug reversed the anticoagulant effect of another completely and rapidly.
